ARTIOS


Associated tags: Cancer Research UK, Netherlands Cancer Institute, Survival, Drug discovery, Novartis, Research, DNA, ATR, Merck Group, DDR, Institute of Cancer Research, Crick, Cancer, Patient, Pharmacokinetics, University, Drug development, DNA repair, Safety, Pharmaceutical industry, MD Anderson Cancer Center, Therapy, Casting Society of America, Ataxia–telangiectasia, Biotechnology

Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Kite, Business, Business administration, Patient, Research, DNA, Fudan University, Acquisition, NYU, MBA, Doctor of Philosophy, DDR, Master of Business Administration, Therapy, Drug development, Investment, RTW

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.

Key Points: 
  • CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.
  • Niall Martin, Chief Executive Officer of Artios, said: “We are delighted to welcome Chris, a prominent research analyst to our Board of Directors.
  • Chris Liu, Ph.D. Board Director of Artios, added: “RTW is now a top shareholder of Artios following the acquisition of Arix and the expansion of our equity interest, which reflects both our confidence and excitement in Artios’ innovative platform targeting broad aspects of the DNA damage response.
  • He currently serves on the board of NiKang Therapeutics, Oricell Therapeutics and Nuance Pharma as a Board Director or Observer.

Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer

Retrieved on: 
Wednesday, February 7, 2024
Principal, Growth, CFO, ATR, Harvard University, DNA, FINRA, IPO, Drug discovery, Biotechnology, Drug development, Cancer, DNA repair, DDR, Business, Management

CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Christine Silverstein as Chief Financial Officer (CFO).

Key Points: 
  • CAMBRIDGE, United Kingdom and NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Christine Silverstein as Chief Financial Officer (CFO).
  • Niall Martin, Chief Executive Officer of Artios, said: “Christine is a seasoned CFO with robust capital markets expertise and a deep understanding of the industry landscape.
  • Christine Silverstein, Chief Financial Officer of Artios, added: “As recognized innovators in DDR drug discovery, Artios’ advanced pipeline targeting the DNA damage response offers cutting-edge approaches for difficult-to-treat cancers.
  • During her time at Abeona Therapeutics, Silverstein operated in multiple senior executive roles including CFO and Principal Financial Officer.

Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

Retrieved on: 
Monday, October 23, 2023
Irinotecan, Phase II, DDR, ATM, Ovarian cancer, ESMO, MD, Ataxia–telangiectasia, Drug development, Pharmacokinetics, PK, Biology, Cancer, DNA repair, Platinum, University, Safety, European Society for Medical Oncology, ATR, MD Anderson Cancer Center, Patient, Toxicity, DNA, Medical imaging, Pharmaceutical industry, Casting Society of America

CAMBRIDGE, United Kingdom and NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, presented promising monotherapy data from the Phase 1/1b portion of the ongoing Phase 1/2a study (NCT04657068) of its ataxia telangiectasia and Rad-3 related (“ATR”) kinase inhibitor ART0380 in advanced or metastatic solid tumors as part of a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023. ART0380 is a clinically advanced, oral, highly potent, and selective ATR inhibitor with best-in-class potential. The Phase 1/1b portion of the trial presented at ESMO assessed the safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ART0380 monotherapy in patients with advanced or metastatic solid tumors. The patient population was enriched for cancers harboring DNA damage response deficiencies as identified by the Artios DcoDeR platform (n = 49).

Key Points: 
  • ART0380 is a clinically advanced, oral, highly potent, and selective ATR inhibitor with best-in-class potential.
  • The Phase 1/1b portion of the trial presented at ESMO assessed the safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ART0380 monotherapy in patients with advanced or metastatic solid tumors.
  • The patient population was enriched for cancers harboring DNA damage response deficiencies as identified by the Artios DcoDeR platform (n = 49).
  • Our next-generation ATR inhibitor ART0380 has demonstrated highly encouraging molecular and clinical responses as a monotherapy particularly in patients with DDR deficiency and high replication stress alterations.

Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

Retrieved on: 
Thursday, October 5, 2023
Ataxia–telangiectasia, Cancer, University, Pharmacokinetics, Drug development, DNA, Safety, ESMO, ATR, European Society for Medical Oncology, Patient, DDR, Combination therapy, Pharmaceutical industry

CAMBRIDGE, United Kingdom and NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the Company will unveil data from the initial Phase 1 study of its ataxia telangiectasia and Rad-3 related (“ATR”) kinase inhibitor ART0380 as part of a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023 taking place October 20 to 24, 2023 in Madrid, Spain.

Key Points: 
  • ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replication stress tumors
    CAMBRIDGE, United Kingdom and NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the Company will unveil data from the initial Phase 1 study of its ataxia telangiectasia and Rad-3 related (“ATR”) kinase inhibitor ART0380 as part of a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023 taking place October 20 to 24, 2023 in Madrid, Spain.
  • ART0380 is a competitive, oral, highly potent, and selective ATR inhibitor undergoing clinical evaluation as monotherapy in patients with solid tumors as well as in combination with chemotherapies in patients with molecularly selected cancers.
  • Monotherapy data presented will include safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy.
  • First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
    Presenter: Kathleen Moore, Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, United States of America
    For more information about Artios Pharma Ltd., please contact:
    Media & Investor Relations Contact:

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

Retrieved on: 
Thursday, February 9, 2023
DNA, MD Anderson Cancer Center, Safety, MD, DNA repair, DDR, Cancer, GEICO, Pharmacokinetics, Irinotecan, Ataxia–telangiectasia, Therapy, University, Founding, Patient, Ovarian cancer, ATR, Neoplasm, Doctor of Philosophy, RECIST, Platinum, Pharmaceutical industry, Casting Society of America

The recommended Phase 2 dose of ART0380 monotherapy has been defined for both intermittent and continuous daily dosing schedules together with the regimen of ART0380 in combination with gemcitabine.

Key Points: 
  • The recommended Phase 2 dose of ART0380 monotherapy has been defined for both intermittent and continuous daily dosing schedules together with the regimen of ART0380 in combination with gemcitabine.
  • Clinically active RECIST confirmed responses occurred across doses and in tumors harboring DDR deficiencies as predicted through Artios’ DcoDeR platform.
  • The favorable pharmacokinetic profile enabling combination with DNA damaging agents offers the potential of a new treatment option for patients with platinum resistant ovarian cancer.
  • ART0380 was originally in-licensed by Artios from The University of Texas MD Anderson Cancer Center and ShangPharma Innovation in 2019.

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Retrieved on: 
Wednesday, August 10, 2022
Merck Group, Institute of Cancer Research, HIV disease progression rates, ATR, PARP, Drug discovery, Breast cancer, Industry, DNA repair, MD Anderson Cancer Center, NEW, The Institute, Toxicity, De novo, Research, Cancer, Neoplasm, Patient, DNA, Therapy, Institute, DDR, Associate, Netherlands Cancer Institute, Biotechnology, Olaparib, Sarah Cannon Research Institute, Safety, Francis Crick Institute, Talazoparib, List of life sciences, Novartis, Partnership, MMEJ, University, ADP, Nature Communications, Cancer Research UK, Medical director, Oncology nursing, Pharmacokinetics, Pharmaceutical industry, Medical imaging, Casting Society of America

ART4215 is the first selective, oral, small molecule inhibitor of the Pol polymerase domain to enter the clinic.

Key Points: 
  • ART4215 is the first selective, oral, small molecule inhibitor of the Pol polymerase domain to enter the clinic.
  • Extensive preclinical studies have demonstrated that ART4215 has broad potential clinical utility, as described in Artios recent Nature Communications publication, Zatreanu et al., 2021.
  • The Pol project was originally in-licensed from Cancer Research Technology (now Cancer Research Horizons) in 2016 as part of the initial formation of Artios.
  • A recommended Phase 2 dose has been established for ART4215 in combination with talazoparib, and a randomized expansion cohort has been initiated to evaluate the combination in patients with BRCA deficient breast cancer.

Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215

Retrieved on: 
Tuesday, September 28, 2021
Therapy, DDR, MMEJ, Cancer, Neoplasm, De novo, Pharmacokinetics, Breast cancer, Cancer Research UK, Novartis, Sarah Cannon Research Institute, DNA, Patient, Medical director, MD Anderson Cancer Center, Institute, Cancer research, Parpi, ATR, Merck, Nature Communications, Associate, Limited partnership, Oncology nursing, University, Safety, List of life sciences, NEW, Industry, PARP, Pharmaceutical industry, Artios, ARTIOS

As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Key Points: 
  • As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
  • www.arixbioscience.com
    Phase 1/2a study evaluating Pol inhibitor, ART4215, in patients with advanced or metastatic solid tumors
    Pol inhibitor, ART4215, is Artios's second investigational new drug to enter the clinic in 2021 along with ATR inhibitor, ART0380
    CAMBRIDGE, UK and NEW YORK, USA, 28 September 2021: Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA Damage Response process in order to treat patients suffering from a broad range of cancers, announces it has dosed the first patient in its Phase 1/2a study with its polymerase theta (Pol) inhibitor, ART4215.
  • The Pol project was originally in-licensed from Cancer Research UK in 2016 as part of the initial formation of Artios.
  • ART4215 is the first selective, orally bioavailable, small molecule inhibitor of the Pol polymerase domain to enter the clinic.

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

Retrieved on: 
Tuesday, January 12, 2021
Given names, Cision, Abid, Names

CAMBRIDGE, England and NEW YORK, Jan. 12, 2021 /PRNewswire/ --Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).

Key Points: 
  • CAMBRIDGE, England and NEW YORK, Jan. 12, 2021 /PRNewswire/ --Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).
  • Prior to joining Artios Pharma, he most recently served as CFO of Precision BioSciences (NASDAQ: DTIL), a next generation genome editing company.
  • Abid Ansari holds a Bachelor of Science degree in chemical engineering and a Master of Business Administration, both from Purdue University.
  • Abid Ansari, Chief Financial Officer of Artios, said: "Artios is a world leader in the field of DNA damage response.

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

Retrieved on: 
Tuesday, January 12, 2021
Given names, Cision, Abid, Names

CAMBRIDGE, England and NEW YORK, Jan. 12, 2021 /PRNewswire/ --Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).

Key Points: 
  • CAMBRIDGE, England and NEW YORK, Jan. 12, 2021 /PRNewswire/ --Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).
  • Prior to joining Artios Pharma, he most recently served as CFO of Precision BioSciences (NASDAQ: DTIL), a next generation genome editing company.
  • Abid Ansari holds a Bachelor of Science degree in chemical engineering and a Master of Business Administration, both from Purdue University.
  • Abid Ansari, Chief Financial Officer of Artios, said: "Artios is a world leader in the field of DNA damage response.

Artios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States

Retrieved on: 
Tuesday, September 24, 2019
Tania

CAMBRIDGE, England and NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States.

Key Points: 
  • CAMBRIDGE, England and NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States.
  • Commenting on the announcement Niall Martin, Chief Executive Officer of Artios Pharma, said:"We are very happy to add Tania with her impressive track-record to our team.
  • "DDR therapies have the potential to transform the way we treat cancer and to dramatically improve outcomes for patients,"said Tania Dimitrova.
  • Tania brings 15 years of bio-pharma business and corporate development, capital markets and investing experience to Artios.